Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Jan 2019
At a glance
- Drugs Semaglutide (Primary)
- Indications Obesity; Overweight
- Focus Therapeutic Use
- Acronyms SELECT; STEP 1
- Sponsors Novo Nordisk
- 21 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 24 Oct 2018 Planned primary completion date changed from 23 Sep 2019 to 2 Mar 2020.
- 08 Aug 2018 According to a Novo Nordisk media release, all four STEP trials are expected to be completed in 2020.